October is Breast Cancer Awareness Month, a month dedicated to raising awareness for breast cancer, spotting early signs and the research being done in the hopes of finding a cure.
Each year in the UK, around 70,000 women are diagnosed with breast cancer, making it one of the most common cancers and a leading cause of cancer-related mortality. While treatment options such as chemotherapy, targeted therapies, and immunotherapy exist, resistance to drugs like Doxorubicin remains a major challenge, limiting effectiveness for many patients.
At Cellomatics, we provide advanced preclinical testing platforms to help researchers overcome these challenges. Using both established cell lines and patient-derived tissues, we offer complex 3D models—including spheroids and organoids—that better replicate tumour architecture and microenvironments than traditional 2D cultures. These models reveal how factors such as drug penetration, cell–cell interactions, and hypoxia affect therapeutic response.
Our co-culture systems, which combine tumour cells with immune effector cells, can further illuminate how therapies might work in combination, helping to identify strategies to overcome drug resistance.
By offering patient-derived tissues, customisable 3D models, and immune co-cultures, Cellomatics supports the development of more predictive preclinical studies, bridging the gap between lab research and effective treatments for breast cancer.
